Lantern Pharma, Inc., a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, has entered into a research and development collaboration with TTC Oncology. The collaboration will focus on leveraging RADR AI insights to advance TTC Oncology’s first- and best-in-class drug candidate TTC-352 for recurrent ER+ breast cancer patients and...